

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re the application of: Andrew Shyjan

Serial No: 09/528,031

Filed: March 17, 2000

For: *Novel Multidrug Resistance-Associated
Polypeptide*

Attorney Docket No: MNI-056CPCN

Group Art Unit:

Examiner:

RECEIVED

JUL 26 2001

TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231
BOX Sequence

4B
KD
7-25-01


Certificate of First Class Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Box Sequence, Washington, D.C. 20231 on the date set forth below.

July 20, 2000

Date of Signature and of Mail Deposit

By:


Debra J. Milasinec
Registration No. 46,931
Attorney for Applicant

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Dear Sir:

Responsive to the Notice to Comply with Requirements for Patent Applications Containing Sequence Disclosures dated June 20, 2001, Applicants' attorney submits the following remarks.

REMARKS

When transmitting the instant application to the U.S. Patent and Trademark Office, Applicants stated, pursuant to 37 CFR 1.821(e), that the computer readable form